For the year ending 2025-12-31, INMB had $3,829K increase in cash & cash equivalents over the period. -$23,624K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -45,933 |
| Stock-based compensation | 9,910 |
| Accretion of debt discount | 0 |
| Gain on settlement of accounts payable | -626 |
| Depreciation expense | 84 |
| Impairment of acquired in-process research and development intangible assets | 16,514 |
| Research and development tax credit receivable | 3,103 |
| Other tax receivable | 29 |
| Prepaid expenses and other current assets | 264 |
| Prepaid expenses related party | 0 |
| Other assets | 516 |
| Accounts payable and accrued liabilities | 1,855 |
| Deferred liabilities | -517 |
| Operating lease liability | 43 |
| Net cash used in operating activities | -22,582 |
| Purchase of fixed assets | 1,042 |
| Net cash used in investing activities | -1,042 |
| Net proceeds from sale of common stock and warrants | 27,544 |
| Cash proceeds for amendment of warrants | 67 |
| Exercise of warrants for cash | 1 |
| Net cash provided by financing activities | 27,612 |
| Impact on cash from foreign currency translation | -159 |
| Net increase (decrease) in cash | 3,829 |
| Cash at beginning of year | 20,922 |
| Cash at end of year | 24,751 |
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)